Cargando…

An Uncommon Incidence of Drug-Induced Immune Hemolytic Anemia Secondary to Ceftriaxone

A 69-year-old female with a history of psoriatic arthritis was diagnosed with septic arthritis and started on broad-spectrum antibiotics. She underwent left hip excisional debridement of her prosthetic hip joint which grew group B Streptococcus (S. agalactiae). She was switched to IV ceftriaxone 2 g...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Aishwarya, Chamberlain, Shannon, Mannuru, Devendranath, Matta, Abhishek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786587/
https://www.ncbi.nlm.nih.gov/pubmed/35106222
http://dx.doi.org/10.7759/cureus.20682
_version_ 1784639143440023552
author Sharma, Aishwarya
Chamberlain, Shannon
Mannuru, Devendranath
Matta, Abhishek
author_facet Sharma, Aishwarya
Chamberlain, Shannon
Mannuru, Devendranath
Matta, Abhishek
author_sort Sharma, Aishwarya
collection PubMed
description A 69-year-old female with a history of psoriatic arthritis was diagnosed with septic arthritis and started on broad-spectrum antibiotics. She underwent left hip excisional debridement of her prosthetic hip joint which grew group B Streptococcus (S. agalactiae). She was switched to IV ceftriaxone 2 g daily and her hemoglobin decreased to 5.4 g/dL on day 11. Peripheral blood smear showed normochromic normocytic anemia and thrombocytopenia without the presence of schistocytes. Increased lactate dehydrogenase (LDH), decreased haptoglobin and hemoglobin, and positive direct Coombs test (DCT) led to a presumptive diagnosis of drug-induced immune hemolytic anemia (DIIHA). As a result, she was switched from ceftriaxone to IV ertapenem 500 mg every 24 hours and oral prednisone 60 mg for four days during the initial phase. Her hemoglobin, LDH, and haptoglobin trended towards normal limits, further supporting the diagnosis of DIIHA secondary to ceftriaxone.
format Online
Article
Text
id pubmed-8786587
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-87865872022-01-31 An Uncommon Incidence of Drug-Induced Immune Hemolytic Anemia Secondary to Ceftriaxone Sharma, Aishwarya Chamberlain, Shannon Mannuru, Devendranath Matta, Abhishek Cureus Emergency Medicine A 69-year-old female with a history of psoriatic arthritis was diagnosed with septic arthritis and started on broad-spectrum antibiotics. She underwent left hip excisional debridement of her prosthetic hip joint which grew group B Streptococcus (S. agalactiae). She was switched to IV ceftriaxone 2 g daily and her hemoglobin decreased to 5.4 g/dL on day 11. Peripheral blood smear showed normochromic normocytic anemia and thrombocytopenia without the presence of schistocytes. Increased lactate dehydrogenase (LDH), decreased haptoglobin and hemoglobin, and positive direct Coombs test (DCT) led to a presumptive diagnosis of drug-induced immune hemolytic anemia (DIIHA). As a result, she was switched from ceftriaxone to IV ertapenem 500 mg every 24 hours and oral prednisone 60 mg for four days during the initial phase. Her hemoglobin, LDH, and haptoglobin trended towards normal limits, further supporting the diagnosis of DIIHA secondary to ceftriaxone. Cureus 2021-12-25 /pmc/articles/PMC8786587/ /pubmed/35106222 http://dx.doi.org/10.7759/cureus.20682 Text en Copyright © 2021, Sharma et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Emergency Medicine
Sharma, Aishwarya
Chamberlain, Shannon
Mannuru, Devendranath
Matta, Abhishek
An Uncommon Incidence of Drug-Induced Immune Hemolytic Anemia Secondary to Ceftriaxone
title An Uncommon Incidence of Drug-Induced Immune Hemolytic Anemia Secondary to Ceftriaxone
title_full An Uncommon Incidence of Drug-Induced Immune Hemolytic Anemia Secondary to Ceftriaxone
title_fullStr An Uncommon Incidence of Drug-Induced Immune Hemolytic Anemia Secondary to Ceftriaxone
title_full_unstemmed An Uncommon Incidence of Drug-Induced Immune Hemolytic Anemia Secondary to Ceftriaxone
title_short An Uncommon Incidence of Drug-Induced Immune Hemolytic Anemia Secondary to Ceftriaxone
title_sort uncommon incidence of drug-induced immune hemolytic anemia secondary to ceftriaxone
topic Emergency Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786587/
https://www.ncbi.nlm.nih.gov/pubmed/35106222
http://dx.doi.org/10.7759/cureus.20682
work_keys_str_mv AT sharmaaishwarya anuncommonincidenceofdruginducedimmunehemolyticanemiasecondarytoceftriaxone
AT chamberlainshannon anuncommonincidenceofdruginducedimmunehemolyticanemiasecondarytoceftriaxone
AT mannurudevendranath anuncommonincidenceofdruginducedimmunehemolyticanemiasecondarytoceftriaxone
AT mattaabhishek anuncommonincidenceofdruginducedimmunehemolyticanemiasecondarytoceftriaxone
AT sharmaaishwarya uncommonincidenceofdruginducedimmunehemolyticanemiasecondarytoceftriaxone
AT chamberlainshannon uncommonincidenceofdruginducedimmunehemolyticanemiasecondarytoceftriaxone
AT mannurudevendranath uncommonincidenceofdruginducedimmunehemolyticanemiasecondarytoceftriaxone
AT mattaabhishek uncommonincidenceofdruginducedimmunehemolyticanemiasecondarytoceftriaxone